Oncotalks | Powered by Novartis

ASH 2018 - Jason R. Gotlib, MD, MS, The New Tool KIT in Advanced Systemic Mastocytosis

ASH
Share this item

Jason R. Gotlib, MD, MS from the Stanford Cancer Institute, Stanford, CA is commenting on the session: The New Tool KIT in Advanced Systemic Mastocytosis

https://ash.confex.com/ash/2018/webprogram/Paper109399.html

1218HEM1089107

Related items

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)

Moshe Mittelman, MD, PhD from the Tel Aviv University, Tel Aviv, Israel is commenting on the abstract: Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)Blood (2019) 134 (Supplement_1): 3740.https://doi.org/10.1182/blood-2019-130309

ASH , Latvia , Lithuania , Estonia , Albania

00:07:06

Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD from the Université de Liège, Liège, Belgium is commenting on the abstract: Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective StudyBlood (2019) 134 (Supplement_1): 37.https://doi.org/10.1182/blood-2019-129992

ASH , Lithuania , Albania

00:03:30

Srdan Verstovsek, MD, PhD; Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Srdan Verstovsek, MD, PhD; Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Srdan Verstovsek, MD, PhD from the MD Anderson Cancer Center, Houston, VS is commenting on the publication: Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response TrialBlood (2019) 134 (Supplement_1): 2947.https://doi.org/10.1182/blood-2019-128101

ASH , Lithuania , Albania

00:02:22

Tom Eyckmans, MD, PhD; ASH 2019 Highlights: Sickle Cell Disease

Tom Eyckmans, MD, PhD; ASH 2019 Highlights: Sickle Cell Disease

Tom Eyckmans, MD, PhD from the Ziekenhuis Netwerk Antwerp, Antwerp, Belgium is commenting on his ASH 2019 Highlights in Sickle Cell Disease

ASH , Lithuania , Albania

00:05:07

Valentina Gaidano, MD, PhD; 3942 Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, PhD; 3942 Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia

Valentina Gaidano, MD, PhD from the University of Turin, Orbassano, Italy is commenting on the abstract: Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid LeukemiaBlood (2019) 134 (Supplement_1): 3942.https://doi.org/10.1182/blood-2019-128085

ASH , Lithuania , Albania

00:03:51

Srdan Verstovsek, MD, PhD; US Optum Database Study in Polycythemia Vera Patients

Srdan Verstovsek, MD, PhD; US Optum Database Study in Polycythemia Vera Patients

Srdan Verstovsek, MD, PhD from the MD Anderson Cancer Center, Houston, VS is commenting on the abstract: US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU FailureBlood (2019) 134 (Supplement_1): 1659.https://doi.org/10.1182/blood-2019-126410

ASH , Lithuania , Albania

00:05:10